Next Virginia LLC

1. AstraZeneca Pharmaceuticals LP $1,690,298 9 payments
2. Astellas Pharma Inc $1,331,428 770 payments
3. AbbVie, Inc. $1,253,700 429 payments
4. Mirati Therapeutics, Inc. $827,815 101 payments
5. BioNTech SE $485,380 85 payments
6. AstraZeneca UK Limited $421,702 9 payments
7. GlaxoSmithKline, LLC. $287,307 57 payments
8. Janssen Research & Development, LLC $283,866 31 payments
9. Boehringer Ingelheim Pharmaceuticals, Inc. $161,242 16 payments
10. Deciphera Pharmaceuticals Inc. $142,371 17 payments

1. A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation $1,331,428 770 payments
2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 $806,470 253 payments
3. A Phase 12a Multi-centre Dose Escalation and Expansion Study of AZD3470 a Methylthioadenosine MTA Cooperative Protein Arginine Methyltransferase 5 PRMT5 Inhibitor as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Metastatic Solid Tumours that are MTAP deficient $655,140 2 payments
4. A Phase I, Multicenter, Open-label, First-in Human, Dose-escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors $563,559 3 payments
5. A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies $530,070 21 payments
6. A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced solid tumors $340,406 5 payments
7. A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalat $287,307 57 payments
8. A Phase I II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer $237,843 3 payments
9. A Modular Phase I IIa Open-label Multi-Centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation $233,755 1 payment
10. Pre-commercial $228,932 37 payments

1. Non-patient care $508,504 18 payments
2. Patient care $261,423 43 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.